http://www.hivandhepatitis.com/2009icr/aasld/docs/111309_a.html
“…Based on these findings, the researchers concluded that the combination of RG7128 and RG7227 for up to 14 days "provided significant antiviral potency in treatment-naive and experienced patients, sustained viral reductions, and appears safe and well-tolerated as a twice-daily oral regimen."
"The results from this study of the RG7227/RG7128 combination raise hopes that we can deliver an interferon-free regimen for our patients in the future," said lead investigator Edward Gane, MD, in a press release issued by InterMune. "Current HCV therapy includes up to 12 months of weekly interferon injections which can be associated with significant side effects. In addition, not all patients can take interferon due to intolerance or contraindications. We look forward to the results of additional studies with these potent compounds."
The collaborating companies announced that Roche will initiate a Phase 2 trial program in the first quarter of 2010. INFORM-2 will assess rapid virological response (undetectable HCV RNA after 4 weeks of therapy) in prior non-responder genotype 1 patients receiving twice-daily RG7128/RG7227 alone and in combination with pegylated interferon alfa-2a, ribavirin, or both. Longer-term studies evaluating sustained virological response (undetectable HCV RNA 24 weeks after completing therapy) are anticipated for the first half of 2010…”
Bill
Hi Josh,
Right now, everything we have to throw at this disease involves interferon. There are new, non-interferon drugs in trial, but they require supplemental IFN to prevent escape variants/mutation.
Roche pharmaceuticals has tested a combo polymerase/protease combo without interferon, but it’s expected this won’t be market available for some time to come… perhaps 7 years or more.
Do you have significant fibrosis? What genotype are you?
Welcome to the discussion group—
Bill